Oppenheimer Issues a Buy Rating on EverQuote (EVER)

Laveta Brigham

In a report released today, Jed Kelly from Oppenheimer assigned a Buy rating to EverQuote (EVER), with a price target of $55.00. The company’s shares closed last Monday at $34.58. According to TipRanks.com, Kelly is a 4-star analyst with an average return of 9.5% and a 48.4% success rate. Kelly […]

In a report released today, Jed Kelly from Oppenheimer assigned a Buy rating to EverQuote (EVER), with a price target of $55.00. The company’s shares closed last Monday at $34.58.

According to TipRanks.com, Kelly is a 4-star analyst with an average return of 9.5% and a 48.4% success rate. Kelly covers the Technology sector, focusing on stocks such as Black Knight, CarGurus, and Square.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for EverQuote with a $62.80 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $63.44 and a one-year low of $21.00. Currently, EverQuote has an average volume of 408.5K.

Based on the recent corporate insider activity of 173 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EVER in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

EverQuote, Inc. operates as an online insurance marketplace connecting consumers with insurance providers. It offers car, home and life insurance. The firm’s data and technology platform matches and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. The company was founded by Seth N. Birnbaum, David B. Blundin, and Tomas Revesz in August 1, 2008 and is headquartered in Cambridge, MA.

Source Article

Next Post

Bayer Posts Third-Quarter Loss on Agriculture Woes

BERLIN—Bayer AG on Tuesday posted a loss in the third quarter as the coronavirus pandemic compounded problems the German chemical and drug giant has been facing since its acquisition of agriculture giant Monsanto just over two years ago. Bayer also said it would need an extra $750,000 on top of […]